Etodolac

General information

Etodolac, a pyranocarboxylic acid, was first marketed in the UK in 1986. By 1988, etodolac had been reported 27 times to the UK Committee on Safety of Medicines as being suspected of causing serious adverse reactions [ ]. In a French postmarketing safety study in 51 355 patients taking 200–600 mg/day, 10% of patients reported a total of 6236 adverse reactions and 9% dropped out because of adverse reactions, 21 of which were judged severe [ ]. In another four postmarketing surveillance studies in 8334 patients with rheumatic conditions who took 200–600 mg/day of etodolac for periods ranging from 4 weeks to 1 year, 23% reported adverse events and 9% stopped taking the drug because of adverse reactions; gastrointestinal events were the most commonly reported [ ].

Organs and systems